REAL WORLD EVIDENCE NEEDS IN ONCOLOGY:
White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid.
Metastatic breast cancer continues to be a significant health challenge in oncology. As the most common cancer in women worldwide, it imposes substantial healthcare burdens and necessitates continuous research and innovation in treatment strategies.
OXON has analyzed the results of the trials presented at ESMO 2023, and examined their potential impact on current clinical guidelines and practices in breast cancer treatment to help guide the RWE gaps by addressing breakthroughs and challenges in treatments across different metastatic breast cancer subtypes.
To download the white paper please complete the following form: